title: [Differential diagnosis and treatment of esophageal stromal tumors and smooth muscle tumors].
abstract: OBJECTIVE
  Esophageal stromal tumors and smooth muscle tumors are not easy to be distinguished in clinic though they have different pathologic features. This study was to compare the clinicopathologic features of esophageal stromal tumors and smooth muscle tumors, and discuss their treatments.
  
  
  METHODS
  The expression of CD117 and CD34 in 16 specimens of primarily diagnosed esophageal leiomyoma, 4 specimens of esophageal leiomyosarcoma, and 1 specimen of stromal tumor was detected by immunohistochemistry. The clinicopathologic features of the patients were analyzed, and the treatment principles and curative efficacies were summarized.
  
  
  RESULTS
  Of the 16 cases of primarily diagnosed esophageal leiomyoma, 5 were CD117(+) and finally diagnosed as non-high aggressive fatal stromal tumor according to the assessment criteria of stromal tumors; 11 were CD117(-). The stromal tumor was CD117(+) and CD34(+), and diagnosed as high aggressive fatal stromal tumor. The 4 cases of primarily diagnosed esophageal leiomyosarcoma were CD117(-) and CD34(-). There was no obvious difference in clinicopathologic manifestations, treatment and prognosis between esophageal non-high aggressive fatal stromal tumor and leiomyoma, and between esophageal high aggressive fatal stromal tumor and leiomyosarcoma.
  
  
  CONCLUSIONS
  Esophageal stromal tumors and smooth muscle tumors can not be distinguished with clinicopathologic exhibitions. The immunohistochemical examination of antibody CD117 is necessary for identifying them. Lumpectomy or esophageal partial resection is enough for esophageal non-high aggressive fatal stromal tumor and leiomyoma. Esophageal partial resection is necessary for esophageal high aggressive fatal stromal tumor and leiomyosarcoma.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China. zsyzhangxu@163.com
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.forename: Tie-Hua
authors.initials: TH
authors.lastname: Rong
authors.forename: Qiu-Liang
authors.initials: QL
authors.lastname: Wu
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Fu
authors.forename: Hao
authors.initials: H
authors.lastname: Long
authors.forename: Lan-Jun
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Guo-Wei
authors.initials: GW
authors.lastname: Ma
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Su
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Li
authors.forename: Dao-Feng
authors.initials: DF
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Hu
authors.forename: Hong
authors.initials: H
authors.lastname: Yang
mesh_terms: D000199:Actins / Q000378:metabolism; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D016629:Esophagectomy / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D007890:Leiomyosarcoma / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016900:Neurofilament Proteins / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*
chemical_list: D000199:Actins; D018952:Antigens, CD34; D016900:Neurofilament Proteins; D019009:Proto-Oncogene Proteins c-kit